Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 42 articles:
HTML format



Single Articles


    January 2024
  1. PETRYLAK DP, Eigl BJ, George S, Heath EI, et al
    Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:63-73.
    PubMed     Abstract available


    December 2023
  2. LINDSKROG SV, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, et al
    Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Clin Cancer Res. 2023;29:4797-4807.
    PubMed     Abstract available


    November 2023
  3. LERNER SP, McConkey DJ, Tangen CM, Meeks JJ, et al
    Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-0602.
    PubMed     Abstract available


  4. GUERCIO BJ, Sarfaty M, Teo MY, Ratna N, et al
    Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Clin Cancer Res. 2023;29:4586-4595.
    PubMed     Abstract available


  5. DRAKAKI A, Powles T, Bamias A, Martin-Liberal J, et al
    Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
    Clin Cancer Res. 2023;29:4373-4384.
    PubMed     Abstract available


    October 2023
  6. KAMRAN SC, Zhou Y, Otani K, Drumm M, et al
    Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
    Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0792.
    PubMed     Abstract available


  7. MITRA A, Thompson B, Strange A, Amato CM, et al
    A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
    Clin Cancer Res. 2023;29:4242-4255.
    PubMed     Abstract available


  8. LI R, Sexton WJ, Dhillon J, Berglund A, et al
    A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
    Clin Cancer Res. 2023;29:3875-3881.
    PubMed     Abstract available


    September 2023
  9. SALARI K, Sundi D, Lee JJ, Wu S, et al
    Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
    Clin Cancer Res. 2023;29:3668-3680.
    PubMed     Abstract available


  10. JIANG D, Lan X, Cai W
    PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
    Clin Cancer Res. 2023;29:3259-3261.
    PubMed     Abstract available


  11. DUAN X, Xia L, Zhang Z, Ren Y, et al
    First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
    Clin Cancer Res. 2023;29:3395-3407.
    PubMed     Abstract available


    August 2023
  12. ZHANG R, Zang J, Jin D, Xie F, et al
    Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer.
    Clin Cancer Res. 2023 Aug 3:CCR-23-0513. doi: 10.1158/1078-0432.CCR-23-0513.
    PubMed     Abstract available


    June 2023
  13. JANG HJ, Hostetter G, Macfarlane AW, Madaj Z, et al
    A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2023;29:2052-2065.
    PubMed     Abstract available


    April 2023
  14. AGGEN DH, Chu CE, Rosenberg JE
    Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Clin Cancer Res. 2023;29:1377-1380.
    PubMed     Abstract available


  15. KLUMPER N, Ralser DJ, Ellinger J, Roghmann F, et al
    Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Clin Cancer Res. 2023;29:1496-1505.
    PubMed     Abstract available


    February 2023
  16. CHRISTENSEN E, Nordentoft I, Birkenkamp-Demtroder K, Elbaek SK, et al
    Cell-free urine- and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer.
    Clin Cancer Res. 2023 Feb 13:CCR-22-3250. doi: 10.1158/1078-0432.CCR-22-3250.
    PubMed     Abstract available


  17. MISHRA A, Kumar D, Gupta K, Lofland G, et al
    Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.
    Clin Cancer Res. 2023;29:581-591.
    PubMed     Abstract available


    January 2023
  18. CHOPRA S, Trepka K, Sakhamuri S, Carretero-Gonzalez A, et al
    Theranostic targeting of CUB domain containing protein 1 (CDCP1) in multiple subtypes of bladder cancer.
    Clin Cancer Res. 2023 Jan 17:CCR-22-1973. doi: 10.1158/1078-0432.CCR-22-1973.
    PubMed     Abstract available


    October 2022
  19. BASILE G, Bandini M, Gibb EA, Ross JS, et al
    Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial.
    Clin Cancer Res. 2022 Oct 3. pii: 709568. doi: 10.1158/1078-0432.CCR-22-2158.
    PubMed     Abstract available


    August 2022
  20. KIM TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, et al
    First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:3452-3463.
    PubMed     Abstract available


  21. ZHU Z, Ma AH, Zhang H, Lin TY, et al
    Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer.
    Clin Cancer Res. 2022 Aug 3. pii: 707432. doi: 10.1158/1078-0432.CCR-22-1362.
    PubMed     Abstract available


    July 2022
  22. SZABADOS B, Ponz-Sarvis M, Machado R, Saldana D, et al
    Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).
    Clin Cancer Res. 2022 Jul 25. pii: 707208. doi: 10.1158/1078-0432.CCR-22-0200.
    PubMed     Abstract available


  23. PIETZAK EJ, Whiting K, Srinivasan P, Bandlamudi C, et al
    Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2022 Jul 14. pii: 707011. doi: 10.1158/1078-0432.CCR-22-1006.
    PubMed     Abstract available


    May 2022
  24. BELLMUNT J, de Wit R, Fradet Y, Climent MA, et al
    Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
    Clin Cancer Res. 2022;28:2050-2060.
    PubMed     Abstract available


    April 2022
  25. GIRARDI DM, Niglio SA, Mortazavi A, Nadal R, et al
    Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2022;28:1353-1362.
    PubMed     Abstract available


    February 2022
  26. SHENG X, Chen H, Hu B, Yao X, et al
    Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.
    Clin Cancer Res. 2022;28:489-497.
    PubMed     Abstract available


    September 2021
  27. WANG H, Mei Y, Luo C, Huang Q, et al
    Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-20-4796.
    PubMed     Abstract available


  28. CHU CE, Sjostrom M, Egusa EA, Gibb EA, et al
    Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
    Clin Cancer Res. 2021;27:5123-5130.
    PubMed     Abstract available


    August 2021
  29. WANG L, Sfakianos JP, Beaumont KG, Akturk G, et al
    Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
    Clin Cancer Res. 2021;27:4287-4300.
    PubMed     Abstract available


  30. WANG L, Sfakianos JP, Beaumont KG, Akturk G, et al
    Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
    Clin Cancer Res. 2021;27:4287-4300.
    PubMed     Abstract available


    July 2021
  31. TEO MY, Rosenberg JE
    NECTIN4 heterogeneity and molecular diversity in bladder cancers: deconstructing the activity of an antibody-drug conjugate.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1807.
    PubMed     Abstract available


  32. KOUTROS S, Rao N, Moore LE, Nickerson ML, et al
    Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
    Clin Cancer Res. 2021;27:3725-3733.
    PubMed     Abstract available


    June 2021
  33. DAMRAUER JS, Roell KR, Smith MA, Sun X, et al
    Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer.
    Clin Cancer Res. 2021 Jun 11. pii: 1078-0432.CCR-21-0205.
    PubMed     Abstract available


    May 2021
  34. DRAKE CG
    Myeloid Resistance is Not Futile: Biomarkers of Immunotherapy in Bladder Cancer.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1011.
    PubMed     Abstract available


  35. HASANALI SL, Morera DS, Racine RR, Hennig M, et al
    HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-21-0422.
    PubMed     Abstract available


  36. BORCSOK J, Diossy M, Sztupinszki Z, Prosz A, et al
    Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-5037.
    PubMed     Abstract available


    April 2021
  37. BORCSOK J, Sztupinszki Z, Bekele R, Gao SP, et al
    Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.
    Clin Cancer Res. 2021;27:2011-2022.
    PubMed     Abstract available


  38. CRABB SJ, Danson S, Catto JWF, Hussain S, et al
    Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
    Clin Cancer Res. 2021;27:1882-1892.
    PubMed     Abstract available


    February 2021
  39. CHANG E, Weinstock C, Zhang L, Charlab R, et al
    FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2021;27:922-927.
    PubMed     Abstract available


  40. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
    A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695).
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-2409.
    PubMed     Abstract available


    January 2021
  41. SHENG X, Yan X, Wang L, Shi Y, et al
    Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2021;27:43-51.
    PubMed     Abstract available


    January 2020
  42. SHARMA P, Sohn J, Shin SJ, Oh DY, et al
    Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.
    Clin Cancer Res. 2020;26:61-70.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.